Shared more. Cited more. Safe forever.
    • advanced search
    • submit works
    • about
    • help
    • contact us
    • login
    View Item 
    •   MOspace Home
    • University of Missouri System
    • Missouri Summits
    • Missouri Regional Life Sciences Summit 2010
    • Abstracts (Missouri Regional Life Sciences Summit 2010)
    • View Item
    •   MOspace Home
    • University of Missouri System
    • Missouri Summits
    • Missouri Regional Life Sciences Summit 2010
    • Abstracts (Missouri Regional Life Sciences Summit 2010)
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    advanced searchsubmit worksabouthelpcontact us

    Browse

    All of MOspaceCommunities & CollectionsDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis SemesterThis CollectionDate IssuedAuthor/ContributorTitleIdentifierThesis DepartmentThesis AdvisorThesis Semester

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular AuthorsStatistics by Referrer

    Neutersol® from Laboratory to Market--Lessons Learned

    Wang, Min
    View/Open
    [PDF] NeutersolLaboratoryToMarket [abstract].pdf (12.66Kb)
    [PDF] NeutersolLaboratoryMarket.pdf (539.9Kb)
    Date
    2010-02
    Contributor
    University of Missouri (System)
    Format
    Poster
    Metadata
    [+] Show full item record
    Abstract
    Even though there is worldwide human and pet overpopulation, it is difficult to secure enough research funding to support development of male contraceptive medicines and devices. The reality is that research funding in general is limited and development of a product from laboratory to market is lengthy and expensive. Neutersol®, an injectable solution for sterilization of male dogs, is the first product approved by the Food and Drug Administration (FDA) for animal sterilization and was marketed in the United States in 2003. The Research and Development (R&D) process used for Neutersol® may serve as a typical model for most male contraceptive medicines and devices developed with limited resources in the United States and worldwide. R&D of the product was done at the University of Missouri-Columbia and was sponsored by a small business venture capital company. The Neutersol® experience with the following questions offers lessons that are applicable to R&D of most male contraceptive medicines and devices. 1. How long is the R&D process from laboratory to market? 2. How is the process for the new product started? 3. What major procedures are required for the product? 4. What are the claims and liability? 5. How is the laboratory data transferred to manufacturing? 6. What is the appropriate procedure for responding to the FDA? 7. How is the labeling technical section finalized? 8. How is the exclusivity of the marketed product extended?
    URI
    http://hdl.handle.net/10355/5491
    Part of
    Abstracts (Missouri Regional Life Sciences Summit 2010)
    Collections
    • Posters (Missouri Regional Life Sciences Summit 2010)
    • Abstracts (Missouri Regional Life Sciences Summit 2010)
    • Reproductive Science and Technology presentations (MU)

    Send Feedback
    hosted by University of Missouri Library Systems
     

     


    Send Feedback
    hosted by University of Missouri Library Systems